Physician profile
Mitchell A Glodowski
NPI 1689602237
$2,519.89
in general payments reported to CMS, 2019-2025
27 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $124 · 2021: $218 · 2022: $200 · 2023: $414 · 2024: $760 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $385.45 | 2019-2023 | Stravix, Stravix Pl, Grafix Xc |
| Amgen INC. | $344.50 | 2024-2025 | Krystexxa, Evenity, Prolia |
| Nevro Corp. | $228.86 | 2022-2024 | Senza |
| Cardiovascular Systems INC. | $172.85 | 2020-2022 | |
| Organogenesis INC. | $168.21 | 2023-2024 | Puraply |
| Koya Medical, INC. | $122.52 | 2024 | Dayspring, Koya Medical |
| Paratek Pharmaceuticals, INC. | $115.06 | 2020-2024 | Nuzyra |
| Horizon Therapeutics Plc | $114.99 | 2021 | |
| Polynovo North America LLC | $100.32 | 2024 | Novosorb Btm |
| Xeris Pharmaceuticals, INC. | $90.09 | 2023-2025 | Gvoke Hypopen |
| Radius Health, INC. | $88.60 | 2023-2025 | Tymlos |
| Averitas Pharma INC. | $83.38 | 2025 | Qutenza |
| Angiodynamics, INC. | $77.98 | 2022 | |
| Tandem Diabetes Care, INC. | $60.97 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $55.36 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.94 | 2023-2024 | Wegovy, Saxenda |
| Stryker Corporation | $32.67 | 2024 | Bioskin |
| Bioventus LLC | $31.10 | 2019 | |
| Abbvie INC. | $27.77 | 2024 | |
| Mallinckrodt Enterprises LLC | $27.26 | 2019 | |
| Apria Healthcare LLC | $25.83 | 2021 | |
| Osiris Therapeutics INC. | $25.69 | 2019 | |
| Ascensia Diabetes Care US INC. | $24.59 | 2025 | |
| Amryt Pharma Holdings LTD | $20.97 | 2023 | Mycapssa |
| Orthofix Medical, INC. | $20.66 | 2024 | Accelstim |
| Medtronic, INC. | $17.69 | 2025 | Propel |
| Sebela Pharmaceuticals INC. | $17.58 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Glodowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.